ICAD (iCAD Corp) Pangali Forward P/E
iCAD, Inc. is implementing eco-friendly AI solutions for oncology diagnostics, eliminating paper-based records from medicine. The company's cloud technologies accelerate data transmission, optimizing clinical logistics. Growth in subscription software effectively balances the hardware segment of the business. This forward P/E chart illustrates the asset's valuation dynamics, where 0.00 determines the current status of the parameter.
Ringkesan rincian data analitis iCAD Corp (ICAD)
- rega saiki lan proyeksi nilai saham:
- indikator valuasi pasar bisnis:
- informasi kapitalisasi buku:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal iCAD, Inc.|ICAD - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang modal iCAD, Inc.|ICAD - Gunggung kewajiban utang perusahaan|Utang-utang marang kapitalisasi buku iCAD Inc.|ICAD - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan iCAD|Rasio cepet icadmed.com
- rincian asil keuangan lan kelipatan valuasi:
ICAD - Bathi perusahaan|Bathi mangsa ngarep iCAD, Inc.|ICAD - Nilai perusahaan marang bathi resik|Pangali Forward P/E iCAD, Inc.|ICAD - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan iCAD Inc.|ICAD - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) iCAD|ICAD - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan icadmed.com|ICAD - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep iCAD, Inc.
Analisis dhasar perusahaan:iCAD
Stable demand for medical innovations from iCAD, Inc. (ICAD) creates a defensive asset profile that remains independent of global macroeconomic fluctuations. Investors should evaluate the ratio of the current price to projected earnings, where the expected P/E multiple for iCAD, Inc. on GURU.Markets allows for determining the extent of overpayment for future cash flows and identifying risks of fundamental business overvaluation.
Pesaing iCAD, Inc.
Prakiraan rega marang bathi ONC (BeiGene)|HALO (Halozyme Therapeutics, Inc.) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E RVMD (RevMed)|AAPG - Prakiraan rega marang bathi|CGON: Prakiraan rega marang bathi|URGN - Pangali Forward P/E|Bicara Therapeutics (BCAX) - Rega marang bathi mangsa ngarep|Personalis Inc - Pangali mangsa ngarep rega marang bathi|ERAS (Erasca Corp) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Delcath Corp DCTH|Pangali Forward P/E YMAB|Kapitalisasi marang proyeksi bathi aurabiosciences.com|Pangali Forward P/E CADL (Candel Therapeutics, Inc.)|ARAY - Prakiraan rega marang bathi|SELLAS Life Sciences Group Inc. - Pangali Forward P/E|ACTU - Pangali Forward P/E|CTOR: Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep HURA|Prakiraan rega marang bathi TARA|FATE: Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E WHWK|Kapitalisasi marang proyeksi bathi tscan.com|Rega marang bathi mangsa ngarep Champions Oncology, Inc. CSBR|XBIT: Rasio rega marang bathi mangsa ngarep|CEL-SCI Corp - Pangali Forward P/E|OS Therapies Inc. (OSTX) - Prakiraan rega marang bathi|RADX (Radiopharm Theranostics Limited) - Prakiraan rega marang bathi|ARTV - Kapitalisasi marang proyeksi bathi|ANL (Adlai Nortye Ltd) - Pangali Forward P/E|verupharma.com (VERU) - Kapitalisasi marang proyeksi bathi|Pangali Forward P/E TPST|Prakiraan rega marang bathi xiliotx.com XLO|Pangali Forward P/E RENB (Renovaro)|Pangali Forward P/E Mural Oncology PLC MURA|Kairos Pharma Inc - Pangali Forward P/E|OKUR (OnKure Therapeutics Inc) - Rasio rega marang bathi mangsa ngarep|GDTC: Pangali Forward P/E|Prakiraan rega marang bathi Curis|APLM (Apollomics Inc.) - Pangali Forward P/E|Pangali Forward P/E Tharimmune Corporation|Rega marang bathi mangsa ngarep Advanced Biomed Inc (ADVB)|genprex.com - Rasio rega marang bathi mangsa ngarep|Pangali Forward P/E CLDI (Calidi Biotherapeutics, Inc.)|SBFM - Prakiraan rega marang bathi|Xenetic Bio - Pangali Forward P/E|Rasio prakiraan rega marang bathi Salarius Pharma|Purple Biotech (PPBT) - Rega marang bathi mangsa ngarep|American Oncology Network, Inc. - Pangali mangsa ngarep rega marang bathi|Prakiraan rega marang bathi BGNE|CKPT: Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E ELEV|Prakiraan rega marang bathi ikenaoncology.com IKNA|Notable Labs, Ltd. - Prakiraan rega marang bathi|Pangali Forward P/E Viracta Therapeutics Inc. VIRX|MOR - Rega marang bathi mangsa ngarep|Pangali mangsa ngarep rega marang bathi NAYA (NAYA Biosciences Inc)|AAPGV: Pangali Forward P/E
